Corvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference

Group 1 - Corvus Pharmaceuticals is set to announce results from cohort 4 of its Phase 1 clinical trial for soquelitinib in patients with moderate to severe atopic dermatitis in the second half of January 2026 [1] - The company has canceled all previously planned conference attendances, including a presentation at the J.P. Morgan 2026 Healthcare Conference scheduled for January 12th [1] - Soquelitinib is an investigational oral small molecule drug that selectively inhibits ITK and is currently in a registration Phase 3 clinical trial for relapsed/refractory PTCL [2] Group 2 - Corvus Pharmaceuticals is pioneering ITK inhibition as a new approach to immunotherapy for various immune diseases and cancer [2] - The company is focused on developing innovative treatments and has a lead product candidate, soquelitinib, which is also in a Phase 1 clinical trial for atopic dermatitis [2]